News Release

Approval for testicular re-implantation to restore fertility after childhood cancer treatment

World first for VUB scientists

Business Announcement

Vrije Universiteit Brussel

Lab of the VUB-Biology of the Testis research group, led by prof. Goossens

image: Lab of the VUB-Biology of the Testis research group, led by prof. Goossens view more 

Credit: (c) Vrije Universiteit BRussel - 2022

VUB scientists get approval for testicular re-implantation to restore fertility after childhood cancer treatment

World first for research group of Professor Ellen Goossens

The research group of Prof Dr Ellen Goossens (VUB) hopes to be the first in the world to re-implant previously removed testicular tissue in men who do not produce sperm cells due to cancer treatment during childhood. The Biology of the Testis research group, led by Goossens, has long been conducting research into the fertility of boys after cancer treatment. Until now, little has been known about this subject. The group’s pioneering research has made Flanders the first region in the world to receive permission to implant frozen testicular tissue that can restore fertility in ex-cancer patients. Since 2002, a total of 128 boys have had their testicular tissue banked at the UZ Brussel for follow-up. Goossens investigated the effects and the possibility of enabling those who do not produce sperm cells to have children. After successful research results, the Ethics Committee has now given the research group permission to re-implant previously collected and frozen testicular tissue in men. This will allow sperm cells to be developed that will be useful in fertility treatment. The group expects to perform the first transplant this year.

Goossens: “The support in the context of Kom op tegen Kanker via the FWO is invaluable for our research. It allowed us to develop a protocol for the preservation and transplantation of testicular tissue. A study is currently under way in which boys who have had tissue banked are further followed up so that we can investigate whether their puberty is proceeding normally and whether they are fertile in adulthood. This is important because too little is still known about the effects of cancer treatments at a young age.”

Ground breaking cancer research in Flanders

Goossens’ research is an example of Flanders’ annual investment in the framework of the cancer charity Kom op tegen Kanker. Flemish minister of science policy Hilde Crevits: “Once again, ground-breaking cancer research by Flemish scientists. Professor Goossens’ research is the ultimate proof that years of investment in cancer research pays off. Cancer is and will remain a disease that many families or groups of friends will encounter sooner or later. Every opportunity for an accelerated diagnosis, better treatment or aftercare should be seized with both hands. That is why, in the framework of Kom op tegen Kanker, we invest each year in promising scientific projects through the Research Foundation – Flanders (FWO). This year we are focusing on better screening for skin and lung cancer and the effect of immunotherapy. We hope that these studies will also yield ground-breaking results in the future.”

Crevits is making €800,000 extra budget available through the Research Foundation – Flanders (FWO). The support goes to three scientific projects carrying out research into better diagnosis or treatment of skin and lung cancer.

  • The first is led by Hilde Bosman (KU Leuven) and with colleagues from UGent and UAntwerp, who are investigating how lung cancer screening using CT scans can be improved. Lung cancer is one of the most common and most deadly cancers. The optimisation of screening is therefore extremely important, as it has already proved to reduce mortality by 26% in men and 41% in women.
  • Lieve Brochez of UGent is carrying out research on improving skin cancer detection by making skin cancer screening in the general population more cost-effective. This should help to ensure that skin cancers can be detected at an early stage and increase the chances of treatment.
  • The third study, led by Jean-Christophe Marine (KU Leuven), aims to further improve the efficiency of immunotherapy, which is already quite successful in the treatment of skin cancer. This research aims to find out why certain patients respond to the therapy and others do not and are therefore resistant to the immunotherapy.


Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.